Multiple Myeloma Regimen Comparisons

Opinion
Video

Gabriel Hinojosa, PharmD, BCOP, reviews head-to-head comparisons in multiple myeloma regimens and evaluates efficacy and safety implications in treatment selection.

This is a video synopsis/summary of an Insights involving Gabriel Hinojosa, PharmD, BCOP.

Hinojosa discussed a rare head-to-head study comparing Dara-RVd (daratumumab [Dara], lenalidomide, bortezomib, dexamethasone) and Dara-KRd (carfilzomib, lenalidomide, dexamethasone) in transplant-eligible patients with multiple myeloma. Although initial observations favored Dara-KRd, further analysis revealed no significant difference between the 2 regimens. With both groups showing high overall response rates, the study suggests that Dara-KRd is as effective as Dara-RVd. This insight allows tailoring quadruplet therapy based on patient-specific factors. Shifting focus to patients ineligible for auto-stem cell transplants, Hinojosa highlighted the MAIA trial’s positive outcomes with Dara-RVd, showing a significant progression-free survival benefit and increased likelihood of achieving stringent complete response and measurable residual disease negativity. This prompted the use of triplet therapy for newly diagnosed transplant-ineligible patients, considering the mild adverse effects of subcutaneous daratumumab administration. Overall, these studies contribute valuable data for optimizing multiple myeloma treatment strategies.

This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.

Related Videos
Video 2 - "Achieving Post-Discharge Success: Goals in Hepatic Encephalopathy Care"
Video 1 - "Identifying and Screening for Hepatic Encephalopathy Risk Factors"
Video 15 - "Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM  "
Video 12 - "Pharmacist Role in Addressing Operational Challenges of  Bispecifics in MM"
Video 12 - "Pharmacist Role in Addressing Operational Challenges of  Bispecifics in MM"
Video 12 - "Pharmacist Role in Addressing Operational Challenges of  Bispecifics in MM"
Video 11 - "Complying with REMS Training and Documentation Requirements"
Video 09 - "Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma"
Video 09 - "Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma"
Related Content
© 2024 MJH Life Sciences

All rights reserved.